Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00152542 · ClinicalTrials.gov registry record · Phase 3
Follow-up at School-age of Children Who Participated in the Efficacy Study of Nitric Oxide for Premature Infants
A Phase 3 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 3
- Development phase
- 160
- Enrollment target
NCT00152542 is a Phase 3 study that has completed, run by University of Chicago. The registered enrollment target is 160 participants.
The verdict
NCT00152542, a Phase 3 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 160 participants
- Enrollment target
Study Summary
Our previous data demonstrated that premature infants treated with inhaled nitric oxide at birth had improved neurodevelopmental outcomes at two years corrected age. We now wish to determine whether this benefit continues through school age.
Interventions
- DRUG Placebo
- DRUG Inhaled nitric oxide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2005-05 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00152542
The ClinicalTrials.gov registry entry for NCT00152542 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00152542 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00152542 about?
NCT00152542 is a clinical study titled "Follow-up at School-age of Children Who Participated in the Efficacy Study of Nitric Oxide for Premature Infants". Our previous data demonstrated that premature infants treated with inhaled nitric oxide at birth had improved neurodevelopmental outcomes at two years corrected age. We now wish to determine whether this benefit continues through school age.
What is the current status of trial NCT00152542?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 160 participants. The study started on 2005-05. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00152542?
The interventions under investigation include: Placebo (DRUG), Inhaled nitric oxide (DRUG).
Who is sponsoring clinical trial NCT00152542?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.